Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc. on July 9, 2026, covering events occurring on July 7, 2026. The Company is an emerging growth company incorporated in Delaware, focused on developing treatments for Alzheimer's disease.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes and Events
- Item 8.01 Other Events: The Company announced the full enrollment of its pivotal Phase 3 clinical trial (NCT06709014) evaluating buntanetap in patients with early Alzheimer's disease.
- Enrollment Details: The trial successfully enrolled 850 patients with pTau217-confirmed AD pathology.
- Site Distribution: Enrollment was conducted across 83 clinical sites in the United States.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard context of clinical trial progression. The primary focus is the operational milestone of reaching full enrollment.
Key Facts for Investor Verification
- Verify the clinical trial identifier NCT06709014 on ClinicalTrials.gov for protocol details and primary endpoints.
- Confirm the definition of "full enrollment" and the expected timeline for data readout in the referenced press release (Exhibit 99.1).
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not provide liquidity data.
- Monitor subsequent filings for any updates on patient retention or data analysis timelines.